GlycoMark Updates for Healthcare Professionals
Caring for Patients with Diabetes
SGLT2 Inhibitors and the GlycoMark Test Issue 22 - February 2020
Study Data Update!
Dear Healthcare Professionals,

As an update to our July report on SGLT2 inhibitors and the GlycoMark 1,5-AG test, we are pleased to summarize new data presented at the ADA Advancing Precision Diabetes Medicine meeting in October. In the study “GlycoMark 1,5-Anhydroglucitol as a Biomarker of SGLT2 Inhibitor Effect”, Dahlen, et al. describe the observed relationship between the GlycoMark 1,5-AG test and the effect of SGLT2 inhibitors.
As shown in Fig 1, patients with diabetes NOT on SGLT2 inhibitor treatment had GlycoMark 1,5-AG test results in the upper ABNORMAL range, indicating recent hyperglycemia and hyperglycemic excursions. Patients with diabetes ON-TREATMENT of an SGLT2 inhibitor had extremely low GlycoMark test results, ≤2 μg/mL, suggesting treatment compliance and desired SGLT2 inhibitor effect.
The optimal cutoff for identifying the SGLT2 inhibitor effect was a GlycoMark result < 2.0 ug/mL, which was validated in an independent dataset... Read More
Educate Your Patients on the GlycoMark Test!
Request Printed Copies
The GlycoMark test complements other tests for diabetes for a more complete assessment of glycemic control. The GlycoMark test can help you identify recent hyperglycemia and hyperglycemic excursions.
How to Order the GlycoMark Test:
LabFinder The GlycoMark test is available through numerous national and regional laboratories, and through LabFinder®. Contact your preferred laboratory for information or download the NEW GlycoMark Test Ordering Guide to identify a laboratory and corresponding test codes.

The GlycoMark Test may be reimbursed by most federal, state and private payers, CPT 84378.

To order test kits for your laboratory, please refer to our online resources and contact us! We are happy to help support you in setting up the test on any open channel chemistry platform.
1Dahlen JR, et al. GlycoMark 1,5-Anhydroglucitol as a Biomarker of SGLT2 Inhibitor Effect. Poster presented at the American Diabetes Association (ADA) Advancing Precision Diabetes Medicine Research Symposium, October 2019, Madrid, Spain.

Dr. Jeff Dahlen is VP of Clinical and Scientific Affairs at GlycoMark.

The Mark newsletter is distributed to healthcare professionals that treat and manage patients with diabetes, and contains the latest updates and important references for the GlycoMark test. This is a complimentary publication provided through the generous support of GlycoMark, Inc.

The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information.

The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not intended to be used to diagnose disease or identify patients that will experience complications of diabetes or the likelihood of experiencing complications.

The information above contains general reimbursement information only and is not legal advice, nor is it advice about how to code, complete, or submit any claim for payment. Providers have the ultimate responsibility for all aspects of coding and billing.

GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo. All other trademarks cited herein are the property of their respective owners. © 2020 GlycoMark, Inc. All Rights Reserved. M-75-1A
805 Third Avenue, 17th Floor, New York, NY 10022
1-888-744-0221 - -